ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant, led by Johnson & Johnson.

Furthest: phase 3, since Sep 4, 20252 company-led studies, 2 open or runningNext primary completion: Jun 21, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson22 open or runningphase 3since Sep 4, 2025Oct 18, 2023Jun 21, 2027phase 1 · NCT06095089
  • Named in Johnson & Johnson’s own pipeline as JNJ-9401, phase 1, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 18, 2023First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT06095089 · 355 planned · United States, Australia, China and more
  2. Sep 4, 2025Phase 3 study in Prostatic Neoplasms, Castration-ResistantNCT07164443 · 1,203 planned · United States, Australia, Belgium and more

Ahead

  1. Jun 21, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT06095089
  2. Aug 18, 2028Primary completion: phase 3 study in Prostatic Neoplasms, Castration-ResistantNCT07164443

TargetBeta

“A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-PSMA/anti-CD28 bispe…”NCIt, read by Claude
“A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07164443Prostatic Neoplasms, Castration-Resistant · United States, Australia, Belgium and more3RecruitingAug 18, 20281,203
NCT06095089Prostatic Neoplasms · United States, Australia, China and more1RecruitingJun 21, 2027355

How it is read

Names in the registry

  • “JNJ-87189401”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.